EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Cerebrospinal Fluid β‐Amyloid and τ Levels in Patients With Iatrogenic Cerebral Amyloid Angiopathy, Sporadic Cerebral Amyloid Angiopathy, Alzheimer Disease, and Controls

Ulf Jensen-Kondering iD, Nils G Margraf iD, Slaven Pikija iD, Kinga Rak-Frattner, Branko Malojcic iD, Senta Frol iD, Janja Pretnar-Oblak iD, Patricia de la Riva iD, Ines Albajar Gomez iD, Jacopo C DiFrancesco iD, Anna Bersano iD, Gregor Kuhlenbäumer iD und 1 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.041908 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Ulf Jensen-Kondering und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroradiology UKSH Campus Lübeck Lübeck Germany. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Alzheimer Disease, Iatrogenic Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Iatrogenic cerebral amyloid angiopathy (iCAA) is a subform of cerebral amyloid angiopathy caused by exposure to amyloid β. The aim of this study was to assess cerebrospinal fluid amyloid and τ concentrations in iCAA in comparison with sporadic cerebral amyloid angiopathy (sCAA), Alzheimer disease (AD), and controls.

Methods

We conducted a systematic literature review to identify patients with iCAA with published cerebrospinal fluid marker concentrations. We then analyzed the cerebrospinal fluid concentrations of amyloid β40, amyloid β42, total τ, and phosphorylated τ 181, comparing them with the corresponding data of patients with sCAA, AD, and controls from our previous work.

Results

The study included 25 patients with iCAA (age, 44±11 years), 31 patients with sCAA (age, 75±5 years), 28 patients with AD (age, 71±8 years) and 30 controls (age, 72±8 years) from 9 case descriptions and 1 cohort study. Amyloid β40 concentrations did not differ significantly between iCAA and the other groups. Amyloid β42 concentration was significantly higher in controls than iCAA and the other groups. The amyloid β42/40 ratio was higher in iCAA than in AD and higher in controls than sCAA and AD. Total τ concentrations were lower in controls than iCAA but did not differ significantly between iCAA, sCAA, and AD. Phosphorylated τ concentrations were not significantly different in iCAA compared with controls, significantly higher in sCAA, and highest in AD.

Conclusions

The observation that phosphorylated τ concentrations in iCAA are not different from controls led us to the hypothesis that iCAA is characterized by amyloid plaque formation largely without concomitant phosphorylated τ aggregation, which is well compatible with most published pathologic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesCerebral Amyloid AngiopathyAlzheimer DiseaseIatrogenic DiseasePeptide Fragmentstau ProteinsHumansAgedBiomarkersMaleFemalePhosphorylationMiddle AgedAdultAged, 80 and overCase-Control Studies

Stichwörter der Autor:innen

Alzheimer diseaseCSFamyloid βamyloid β40amyloid β42iatrogenic cerebral amyloid angiopathyphosphorylated τtotal ττ

Substanzen

Amyloid beta-PeptidesBiomarkersPeptide Fragmentstau Proteinsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Department of Neuroradiology UKSH Campus Lübeck Lübeck Germany.
  • Department of Radiology and Neuroradiology, UKSH Campus Kiel Kiel Germany.
  • Department of Neurology, UKSH Campus Kiel, Kiel University Kiel Germany.
  • Department of Neurology Christian Doppler University Hospital Salzburg Austria.
  • Department of Neurology Krankenhaus der Barmherzigen Brüder Eisenstadt Austria.
  • Department of Neurology Zagreb School of Medicine, University Hospital Center Zagreb Croatia.

ORCID-Profile: Ulf Jensen-Kondering, Nils G Margraf, Slaven Pikija, Branko Malojcic, Senta Frol, Janja Pretnar-Oblak, Patricia de la Riva, Ines Albajar Gomez, Jacopo C DiFrancesco, Anna Bersano, Gregor Kuhlenbäumer, Benedetta Storti

Zitieren

APA

Jensen-Kondering, U., Margraf, N. G., Pikija, S., Rak-Frattner, K., Malojcic, B., Frol, S., Pretnar-Oblak, J., de la Riva, P., Albajar Gomez, I., DiFrancesco, J. C., Bersano, A., Kuhlenbäumer, G., & Storti, B. (2025). Cerebrospinal Fluid β‐Amyloid and τ Levels in Patients With Iatrogenic Cerebral Amyloid Angiopathy, Sporadic Cerebral Amyloid Angiopathy, Alzheimer Disease, and Controls. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041908

Vancouver

Jensen-Kondering U, Margraf NG, Pikija S, Rak-Frattner K, Malojcic B, Frol S, et al. Cerebrospinal Fluid β‐Amyloid and τ Levels in Patients With Iatrogenic Cerebral Amyloid Angiopathy, Sporadic Cerebral Amyloid Angiopathy, Alzheimer Disease, and Controls. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041908

BibTeX
@article{JensenKondering2025,
  author = {Jensen-Kondering, Ulf and Margraf, Nils G and Pikija, Slaven and Rak-Frattner, Kinga and Malojcic, Branko and Frol, Senta and Pretnar-Oblak, Janja and de la Riva, Patricia and Albajar Gomez, Ines and DiFrancesco, Jacopo C and Bersano, Anna and Kuhlenbäumer, Gregor and Storti, Benedetta},
  title = {Cerebrospinal Fluid β‐Amyloid and τ Levels in Patients With Iatrogenic Cerebral Amyloid Angiopathy, Sporadic Cerebral Amyloid Angiopathy, Alzheimer Disease, and Controls},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.041908}
}
Kostenlos starten →